UNASSIGNED: @entity740 ( @entity740 ) is a worldwide public health problem that affects millions of @entity1 from all racial and ethnic groups. At end of 2013, over 300,000 Japanese @entity1 had maintenance dialysis therapy (JSDT). In Japan, the major causes of @entity454 ( @entity454 ) are chronic @entity631 (particularly @entity8 ), type 2 @entity2316 , and hypertensive @entity9161 . @entity101 is a major factor driving the progression of @entity740 to @entity454 . Since many features of the pathogenesis of @entity8 are still obscure, specific treatment is not yet available. However, efforts by investigators around the world have gradually clarified different aspects of the pathogenesis and treatment of @entity8 . Today, around half of all @entity6 @entity1 in Japan receive medical treatment. Type 2 @entity2316 is one of the major long-term microvascular complications occurring in nearly 40% of Japanese @entity6 @entity1 . The pathogenesis of @entity2316 involves both genetic and environmental factors. However, the candidate genes related to the initiation and progression of the disorder are still obscure in @entity1 with @entity2316 . Regarding environmental factors, the @entity137 of persistent @entity4854 , reactive @entity26 species, systemic and/or glomerular @entity101 , @entity2299 and complement are considered to play an important role. The first part of this review covers the pathogenesis of @entity8 and type 2 @entity2316 , and combines the clinicopathological findings in @entity1 with our research on the ddY and KKA-y @entity19 models (spontaneous animal models for @entity8 and @entity2316 , respectively). In Japan, the major renal replacement therapies (RRT) are @entity298 ( @entity298 ) and hemodialysis (HD). The second part of this review focuses on @entity298 and HD. Based on our research findings from @entity1 and as well as from animal models, we discuss strategies for the management of @entity1 on @entity298 and HD.    2015 S. Karger AG, Basel.

Pathogenesis and Treatment of XXXX : A Review of Our Recent Basic and Clinical Data.

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity8 :: ('MESH:D007674', 'Disease') :: ['IgA nephropathy'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy'] @entity9161 :: ('MESH:D009400', 'Disease') :: ['nephrosclerosis'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity740 :: ('MESH:D051436', 'Disease') :: ['Chronic kidney disease', 'CKD'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESKD', 'end stage kidney disease']
@entity740 :: (MESH:D051436,Disease) :: ['Chronic Kidney Disease']
